SeaStar Medical Holding Corporation (ICU)
| Market Cap | 16.10M +5.8% |
| Revenue (ttm) | 1.71M +123.6% |
| Net Income | -13.63M |
| EPS | -3.81 |
| Shares Out | 5.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,263 |
| Open | 3.010 |
| Previous Close | 3.010 |
| Day's Range | 2.890 - 3.130 |
| 52-Week Range | 2.070 - 7.350 |
| Beta | -1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 12, 2026 |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SC... [Read more]
Financial Performance
In 2025, SeaStar Medical Holding's revenue was $1.23 million, an increase of 814.07% compared to the previous year's $135,000. Losses were -$12.15 million, -51.07% less than in 2024.
Financial StatementsNews
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
Award recognizes Dr. Chung's extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support
SeaStar Medical granted Breakthrough Device Designation for SCD therapy
SeaStar Medical (ICU) announced that the FDA has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device, or SCD, therapy for the treatment of hyperinflammation i...
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, ...
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
DENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), a commercial-stage healthcare company focused on transformational treatments for critical...
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients fa...
SeaStar Medical announces codes available for use of SCD therapy for AKI
SeaStar Medical (ICU) announced that effective October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD the...
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical's SCD Therapy for Acute Kidney Injury (AKI)
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future pote...
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ® , an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
SeaStar Medical Congratulates H. David Humes, M.D.
Prestigious honor recognizes Dr. Humes' pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric pa...
SeaStar Medical Holding Transcript: H.C. Wainwright 28th Annual Global Investment Conference
At the H.C. Wainwright conference, a novel therapy for organ failure was highlighted, showing strong pediatric results and advancing pivotal adult trials. The company targets significant market expansion, with regulatory and reimbursement milestones expected by 2027.
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients f...
SeaStar Medical Holding Earnings Call Transcript: Q2 2026
QUELIMMUNE revenue grew 82% year-over-year in Q2 2026, with adoption doubling among top pediatric hospitals. NEUTRALIZE-AKI trial for adult AKI is progressing, with enrollment on track and regulatory milestones supported by FDA designations.
SeaStar Medical Holding Earnings release: Q2 2026
SeaStar Medical Holding released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
SeaStar Medical Holding Quarterly report: Q2 2026
SeaStar Medical Holding has published its Q2 2026 quarterly earnings report on August 12, 2026.
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
Added 3 top-rated children's hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025
SeaStar Medical Holding Slides: Investor presentation
SeaStar Medical Holding has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients fa...
SeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)
Sponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Med...
SeaStar Medical Holding Transcript: Investor Summit Virtual Conference
SCD therapy targets hyperinflammation at its source, showing strong survival benefits and no device-related adverse events in pediatric AKI, with a robust pipeline expanding into adult and cardiorenal indications. Commercialization is advancing, supported by FDA approvals, CMS reimbursement, and a clean financial position.
SeaStar Medical announces new CD-10-PCS codes for SCD therapy
SeaStar Medical (ICU) announced that its Selective Cytopheretic Device, or SCD, therapy has received dedicated ICD-10-PCS codes from the Centers for Medicare & Medicaid Services, or CMS. This assignme...
SeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney Injury
Enables standardized inpatient hospital billing for QUELIMMUNE ® (SCD-PED) therapy
SeaStar Medical to Present at Upcoming Investor Summit Conference
DENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients fa...
SeaStar Medical price target raised to $8 from $6 at Maxim
Maxim analyst Anthony Vendetti raised the firm’s price target on SeaStar Medical (ICU) to $8 from $6 and keeps a Buy rating on the shares. The company’s Q1 revenue, gross…
SeaStar Medical Holding Earnings Call Transcript: Q1 2026
QUELIMMUNE net revenue grew 69% year-over-year in Q1 2026, with seven new hospital adoptions and strong gross margins. The NEUTRALIZE-AKI pivotal trial for adult AKI is progressing, and the SAVE Registry reached 50-patient enrollment. Cash reserves increased to $9.3 million.
SeaStar Medical Holding Earnings release: Q1 2026
SeaStar Medical Holding released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.